Comparison of China-Europe examination of patient-group-specific medical use patents under the background of precision medicine:from the perspective of patient population based on physiological indicators
LI Yan-li
Abstract：This paper focuses on the field of precision medicine,taking the invalidation request case of the invention patent titled"Use of Degarelix in the Preparation of a Medicament for Treating Metastatic Prostate Cancer",which was one of the top ten patent reexamination and invalidation cases of 2024,as a starting point.By combining classic cases from the European Patent Office and examination practices in China and Europe,this paper provides an in-depth analysis of the differences and evolving trends in the examination of invention patents related to patient-group-specific medical uses between China and Europe.The paper aims to provide insights for pharmaceutical R&D enterprises,patent practitioners,and relevant policy makers,thereby supporting the healthy development of patent innovation and protection in the pharmaceutical field.
Keywords：precision medicinepatient populationphysiological indicatorsdisease subtypescope of protection
Publication Date：2026-03-30
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：6( 561-566 )